Lo que necesita saber Las dosis de refuerzo de la...Leer más
CHAPEL HILL, NC, USA, (April 20, 2021) – As a complement to its recent statement on blood clots associated with COVID-19 vaccination, the International Society on Thrombosis and Haemostasis (ISTH) has issued interim guidance for the diagnosis and treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT). This guidance, which builds upon the work of our international partners, should be used to inform the management of suspected thrombosis in subjects who have recently received the AstraZeneca or Johnson & Johnson vaccines.
View the guidance here and download a diagnostic flowchart here. The ISTH COVID-19 Response Task Force, represented by an international committee of medical leaders, informed and reviewed this guidance, finalized on April 20, 2021.
As a reminder, the ISTH reiterates that COVID-19 is associated with a risk of hospitalization and death. The reported combination of blood clots and low blood platelets is exceedingly rare, and the overall benefits of the AstraZeneca vaccine and the Johnson & Johnson vaccine outweigh the risks of these rare thromboembolic side effects.
Addendum: On April 22, 2021 the ISTH Scientific and Standardization Committee (SSC) published new recommendations for the clinical and laboratory diagnosis of vaccine‐induced immune thrombotic thrombocytopenia (VITT). See them here in the Journal of Thrombosis and Haemostasis (JTH).
Créditos: Comité científico Covid